Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2027

Conditions
Tuberous Sclerosis ComplexEpilepsy
Interventions
DRUG

Sirolimus

The investigational drug product to be used in this study is sirolimus, provided in oral suspension.

DRUG

Placebo

Matching placebo

Trial Locations (11)

27510

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

RECRUITING

Lurie Children's Hospital of Chicago, Chicago

63110

RECRUITING

Washington University -- St. Louis, St Louis

77030

RECRUITING

University of Texas HSC at Houston, Houston

80045

RECRUITING

Children's Hospital Colorado, Aurora

90095

RECRUITING

University of California at Los Angeles, Los Angeles

94304

RECRUITING

Stanford University, Palo Alto

98105

RECRUITING

Seattle Children's Hospital, Seattle

02115

RECRUITING

Boston Children's Hospital, Boston

All Listed Sponsors
lead

Darcy Krueger

OTHER